{
    "clinical_study": {
        "@rank": "120931", 
        "acronym": "LYMRIT-37-01", 
        "arm_group": {
            "arm_group_label": "Betalutin", 
            "arm_group_type": "Experimental", 
            "description": "Betalutin, 10 MBq/kg b.w., in escalated doses."
        }, 
        "brief_summary": {
            "textblock": "This study is a phase I/II, open-label study in patients with relapsed CD37 positive\n      non-Hodgkin lymphoma.  The Phase I part of the study is a dose escalating study to define\n      the maximum tolerable dose of 177Lu-DOTA-HH1 (Betalutin), assess safety and toxicity,\n      pharmacokinetics, biodistribution and efficacy. After completion of the phase I study, a\n      dose will be selected for the phase II part of the study which is designed to investigate\n      tumour response rate, progression free survival, confirmation of the selected dose as well\n      as safety and toxicity."
        }, 
        "brief_title": "A Phase I/II Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma", 
        "completion_date": {
            "#text": "March 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-Hodgkin Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Histologically confirmed (by WHO classification) relapsed incurable non-Hodgkin\n             B-cell lymphoma of following subtypes; follicular grade I-IIIA, marginal zone, small\n             lymphocytic, lymphoplasmacytic, mantle cell.\n\n          2. Age \u2265 18 years\n\n          3. A pre-study WHO performance status of 0-1\n\n          4. Life expectancy should be \u2265 3 months\n\n          5. <25% tumour cells in bone marrow biopsy\n\n          6. CD37+, re-biopsy or test on existing tumour material if not known.\n\n          7. Measurable disease by radiological methods\n\n          8. Women of childbearing potential must:\n\n               1. understand that the study medication is expected to have teratogenic risk\n\n               2. have a negative pregnancy test\n\n               3. agree to use, and be able to comply with, effective contraception without\n                  interruption, 4 weeks before starting study drug, throughout study drug therapy\n                  and for 5 months after end of study drug therapy, even if she has amenorrhoea\n\n          9. Male subjects must agree to use condoms during intercourse throughout study drug\n             therapy and the following 5months\n\n         10. Patients previously treated with native rituximab are eligible\n\n         11. The patient is willing and able to comply with the protocol, and agrees to return to\n             the hospital for follow-up visits and examination\n\n         12. The patient has been fully informed about the study and has signed the informed\n             consent form\n\n        Exclusion Criteria:\n\n          1. Medical contraindications, including uncontrolled infection, severe cardiac,\n             pulmonary, neurologic, psychiatric or metabolic disease, steroid requiring\n             asthma/allergy, known HIV positive\n\n          2. Laboratory values within 15 days pre-registration:\n\n               1. Absolute Neutrophil Counts (ANC) \u2264 1.5 x 109 /l\n\n               2. Platelet count \u2264 150 x 109 /l\n\n               3. Total bilirubin \u2265 30 mmol/l\n\n               4. ALP and ALAT \u2265 4x normal level)\n\n               5. Creatinine \u2265 110 \u00b5mol/l (men), 90 \u00b5mol/l (women))\n\n               6. IgG \u2264 3 gr/l\n\n          3. Known CNS involvement of lymphoma\n\n          4. Previous total body irradiation, or irradiation of > 25% of the patient's bone marrow\n\n          5. Known history of HAMA\n\n          6. Chemotherapy or immunotherapy received within the last 4 weeks prior to start of\n             study treatment. Pretreatment with rituximab is allowed.\n\n          7. Pregnant or lactating women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01796171", 
            "org_study_id": "EudraCT: 2011-000033-36"
        }, 
        "intervention": {
            "arm_group_label": "Betalutin", 
            "description": "Dose finding study, starting on 10 MBq/kg b.w. Betalutin (177Lu-Dota-tetulomab), single injection.", 
            "intervention_name": "Betalutin", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Radioimmunotherapy", 
            "Lu-177", 
            "Phase I study", 
            "Phase II study", 
            "Betalutin"
        ], 
        "lastchanged_date": "February 19, 2013", 
        "location": [
            {
                "contact": {
                    "email": "ARNEK@ous-hf.no", 
                    "last_name": "Arne Kolstad, MD", 
                    "phone": "+47 22934000"
                }, 
                "facility": {
                    "address": {
                        "city": "Oslo", 
                        "country": "Norway", 
                        "zip": "0310"
                    }, 
                    "name": "Oslo University Hospital"
                }, 
                "investigator": {
                    "last_name": "Arne Kolstad, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Martin Erlanson, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Ume\u00e5", 
                        "country": "Sweden"
                    }, 
                    "name": "Norrlands University Hospital"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Norway", 
                "Sweden"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I/II Study of 177Lu-HH1 (Betalutin)Radioimmunotherapy for Treatment of Relapsed CD37+ Non-Hodgkin Lymphoma", 
        "overall_contact": {
            "email": "bb@nordicnanovector.no", 
            "last_name": "Bj\u00f8rg Bolstad", 
            "phone": "+47 22 58 00 04"
        }, 
        "overall_official": {
            "affiliation": "Oslo University Hospital", 
            "last_name": "Arne Kolstad, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Norway: Norwegian Medicines Agency", 
                "Norway: Regional Ethics Commitee", 
                "Sweden: Medical Products Agency", 
                "Sweden: Regional Ethical Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Patients are closely monitored during and after injection of Betalutin over a 12 week period. Thereafter, at certain intervals up to 5 years. Safety evaluations are vital signs, physical examination, hematology and serum biochemistry.\nAdverse events and abnormal laboratory values will be graded for toxicity according to CTCAE version 4.", 
            "measure": "Safety/Dose limiting toxicity", 
            "safety_issue": "Yes", 
            "time_frame": "12 weeks"
        }, 
        "reference": [
            {
                "PMID": "23267131", 
                "citation": "Dahle J, Repetto-Llamazares AH, Mollatt CS, Melhus KB, Bruland OS, Kolstad A, Larsen RH. Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma. Anticancer Res. 2013 Jan;33(1):85-95."
            }, 
            {
                "PMID": "23256748", 
                "citation": "Repetto-Llamazares AH, Larsen RH, Mollatt C, Lassmann M, Dahle J. Biodistribution and Dosimetry of 177Lutetulomab, a New Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma. Curr Radiopharm. 2012 Dec 13. [Epub ahead of print]"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01796171"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "CT or PET/CT imaging will be used to quantify changes in lesions on baseline imaging, with responses classified according to revised response criteria for NHL (Cheson, 2007.)", 
            "measure": "Efficacy", 
            "safety_issue": "No", 
            "time_frame": "3 months - 5 years"
        }, 
        "source": "Nordic Nanovector", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Nordic Nanovector", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}